Catalyst Event

Chong Kun Dang Pharm Co (185750) · Other

From KRX Bio Technology Transfer Index (KBIOTT)

3/20/2026, 12:00:00 AM

OtherSentiment: Positive

Partner Novartis specified the development direction for the previously out-licensed drug candidate 'CKD-510', targeting atrial fibrillation in a Phase 2 trial.

Korean Translation

기술수출 신약 후보물질 'CKD-510'에 대해 파트너사 노바티스가 심방세동을 대상으로 임상 2상 개발 방향을 구체화함.

Related Recent Events

View Full Timeline